Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ABUSBullishCorporate Developmentsnews

High materiality7/10

Arbutus completes $230 million share buyback, reducing float by about 23%

Oct 1, 2026, 7:53 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

A sizable $230M buyback reduces float by ~23%, including a 46M shares bought at $5.00; typically supports the stock, improves per-share metrics, and can spark short-term gains, especially with an oversubscribed tender and a known settlement date.

AI summary

What happened, with direct paths to the underlying reporting

Arbutus Biopharma announced the final results of a $230 million tender offer to repurchase 46 million shares at $5.00, equating to roughly 23% of outstanding shares. The buyback leaves about 153.3 million shares outstanding and could lift near-term per-share metrics, though it does not alter the company’s clinical development trajectory. Roivant maintains ~19.5% ownership post-close, with settlement anticipated around October 5, 2026.

Arbutus buys 46M shares for $230M via Dutch auction; ~23% of float.
Post-offer outstanding shares ~153.3M; 65.71M tendered, 55.6% taken in auction.
Roivant maintains ~19.5% stake after completion.
Settlement expected Oct 5, 2026; no Canadian deemed dividend expected.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.